ReviewBioactive materials2025
Advances in cold atmospheric plasma therapy for cancer.
Review in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Cold Atmospheric Plasma Reduces Migration and Viability of Oral Squamous Cell Carcinoma Cells and Increases E-Cadherin Expression.Current issues in molecular biology · 2026Article
- Possible Applications of Cold Atmospheric Plasma in Otorhinolaryngology: A Narrative Review.Antioxidants (Basel, Switzerland) · 2026Review
- All-Flex Plasma Patch for In Vivo Delivery of Reactive Species.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Effects of helium cold atmospheric plasma (CAP) on HT-29 cancer stem cell spheroid.Scientific reports · 2026Article
- Pressurized intraperitoneal cold atmospheric plasma as a novel therapeutic strategy for peritoneal metastatic carcinoma.Journal of advanced research · 2026Article
- Cold Atmospheric Plasma in Biomedicine and Pharmacology: Multidisciplinary Perspectives on Therapeutic Applications.ACS pharmacology & translational science · 2026Review
- Immune-Centered Cross-Talk Between Cancer Cells and the Tumor Microenvironment-Implications for Therapy.Cancers · 2026Review
- Inhibitory effects of cold atmospheric plasma-activated solution on cutaneous squamous cell carcinoma.Frontiers in pharmacology · 2026Article
- Electrochemical Detection of NO and CaPlasma chemistry and plasma processing · 2026Article
- Modulation of cellular signaling and innate immune mechanisms by cold atmospheric plasma.Frontiers in immunology · 2026Review
- Modulating the glioma microenvironment with laser interstitial thermal therapy: mechanisms and therapeutic implications.Journal of neuro-oncology · 2025Review
- Cold Atmospheric Plasma Selectively Targets Neuroblastoma: Mechanistic Insights and In Vivo Validation.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cold atmospheric plasma (CAP) has emerged as a promising, non-invasive therapeutic strategy for cancer treatment, leveraging reactive species to selectively induce cancer cell death while sparing healthy tissues. This review summarizes the underlying mechanisms of CAP-mediated anti-cancer effects, including apoptosis, immunogenic cell death, pyroptosis, ferroptosis, necrosis, and modulation of the tumor immune microenvironment. Moreover, we highlight recent advances in CAP-based therapies, including direct CAP treatment and indirect approaches assisted by various delivery methods, encompassing fluids, hydrogels, tubes, and microneedles. Additionally, we survey the clinical efforts of CAP therapy for cancer. Overall, CAP represents a novel and versatile cancer treatment modality with significant translational potential. Continued research into its mechanisms, safety, and optimization strategies will be essential to harness its clinical benefits and expand its application across different cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.